News

Article

The Prostate Cancer Demon

Author(s):

Peter O'Connor

My prostate cancer has come back and stronger, but so have I.

Image of a doctor showing his patient images on a tablet.

The Demon

I’ll face the demon,

I thought I beat years ago.

You’re back and stronger this time,

but so am I, so am I.

I wasn’t looking for this fight,

I was happy without you.

But you forced your way

back into my life

More doctors, more oncologists,

more blood drawn,

more drugs.

All looking to beat you.

So bring it on, let’s go!

I have an army behind me,

Doctors, family and friends

I’m ready for you.

This post was written and submitted by Peter O'Connor. The article reflects the views of O'Connor and not of CURE®. This is also not supposed to be intended as medical advice.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of thumbnail.
Image of Dr. Deville.
Image of Doctor.
Image of Dr. Tagawa.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Image of smiling doctor.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Related Content
Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer: © stock.adobe.com.
June 13th 2025

Similar Outcomes Yielded Between Surgery and Radiation in Low-Risk Prostate Cancer

Spencer Feldman
Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of bottle
June 6th 2025

Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation

Roman Fabbricatore
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Nubeqa/ADT treatment led to positive impacts on HRQoL vs placebo in mHSPC: © stock.adobe.com.
June 4th 2025

Nubeqa Combo Positively Impacts HRQoL vs Placebo in Prostate Cancer Subgroup

Sabrina Serani
Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.
The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.
June 3rd 2025

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

Spencer Feldman
The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.